These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8710045)

  • 1. Suggestive evidence for bromocriptine-induced pleurisy.
    Klaassen RJ; Troost RJ; Verhoeven GT; Krepel HP; van der Lely AJ
    Neth J Med; 1996 Jun; 48(6):232-6. PubMed ID: 8710045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos.
    Hillerdal G; Lee J; Blomkvist A; Rask-Andersen A; Uddenfeldt M; Koyi H; Rasmussen E
    Eur Respir J; 1997 Dec; 10(12):2711-5. PubMed ID: 9493648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A pleurisy that can speak of her].
    Bulckaen H; Fauchais AL; Michon-Pasturel U; Queyrel V; Hachulla E; Hatron PY; Devulder B
    Rev Med Interne; 2000 Jun; 21 Suppl 3():333s-335s. PubMed ID: 10916847
    [No Abstract]   [Full Text] [Related]  

  • 4. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
    McElvaney NG; Wilcox PG; Churg A; Fleetham JA
    Arch Intern Med; 1988 Oct; 148(10):2231-6. PubMed ID: 3178380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleural effusion during bromocriptine exposure in two patients with pre-existing asbestos pleural plaques: a relationship?
    Knoop C; Mairesse M; Lenclud C; Gevenois PA; De Vuyst P
    Eur Respir J; 1997 Dec; 10(12):2898-901. PubMed ID: 9493681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pleuropneumopathy caused by bromocriptine in a patient with Parkinson disease. Review of the literature apropos of a new case].
    Debove P; Simon F; Vaylet F; Renard JL; L'Her P
    Ann Med Interne (Paris); 1998 Apr; 149(3):167-71. PubMed ID: 11490541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleuropulmonary reactions in patients on bromocriptine treatment.
    Tornling G; Unge G; Axelsson G; Noring L; Granerus AK
    Eur J Respir Dis; 1986 Jan; 68(1):35-8. PubMed ID: 3948932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease.
    Anglès A; Bagheri H; Saivin S; Montastruc JL
    Therapie; 2002; 57(4):408-10. PubMed ID: 12422563
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Goetz CG; Tanner CM; Glantz RH; Klawans HL
    Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases.
    Champagne S; Coste E; Peyrière H; Nigond J; Mania E; Pons M; Hillaire-Buys D; Balmes P; Blayac JP; Davy JM
    Ann Pharmacother; 1999 Oct; 33(10):1050-4. PubMed ID: 10534217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Severe pleuropericarditis induced by long-term bromocriptin therapy, report of a case and review of the literature].
    Ciubotaru V; Poinsignon Y; Brunet-Bourgin F; Mestassi M; Rosenbaum D
    Rev Med Interne; 2004 Apr; 25(4):310-4. PubMed ID: 15050800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleuropulmonary involvement during bromocriptine treatment.
    Kinnunen E; Viljanen A
    Chest; 1988 Nov; 94(5):1034-6. PubMed ID: 3180854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diffuse interstitial lung disease without pleural involvement and high-dose bromocriptine].
    Marsaudon E; Castet D; Barrault MF; Allais C
    Rev Mal Respir; 1997 Nov; 14(5):405-7. PubMed ID: 9480488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleuropulmonary disease as a side-effect of treatment with bromocriptine.
    Comet R; Domingo C; Such JJ; Ribera G; Sans J; Marín A
    Respir Med; 1998 Sep; 92(9):1172-4. PubMed ID: 9926176
    [No Abstract]   [Full Text] [Related]  

  • 16. Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine.
    Kains JP; Hardy JC; Chevalier C; Collier A
    Acta Clin Belg; 1990; 45(5):306-10. PubMed ID: 2177299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-induced pleurisy].
    Benard A; Guenanen H; Tillie-Leblond I; Wallaert B
    Rev Mal Respir; 1996 Jul; 13(3):227-34. PubMed ID: 8765914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.
    Giménez-Roldán S; Esteban EM; Mateo D
    Clin Neuropharmacol; 2001; 24(6):346-51. PubMed ID: 11801810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
    Marsden CD
    Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.